

- Saquinavir
 drug interactions of, 246e-3t
 metabolism of, 34t
 molecular structure of, 1276f
 resistance to, 1280f
- Sarcoglycans, 462e-8, 462e-8f
- Sarcoidosis, **2205**
 clinical features of, **2206**, 2206t
 alopecia, 355, 355t
 azotemia, 292
 bone marrow involvement, 2208
 breast lesions, 2209
 cardiac, 290e-1t, 2208
 AV conduction block, 271e-7f, 1471, 1471t
 myocarditis, 1561, 1562f
 ventricular tachycardia, 1495
 cough, 244
 cutaneous
 characteristics of, 367, 1443, 2207
 figurate lesions, 356, 356t
 hypopigmentation, 357t
 lupus pernio, 364t, 367, 2207, 2207f
 maculopapular lesions, 76e-17f, 2207, 2207f
 extrahepatic cholestasis, 284
 facial palsy, 2648
 hepatic, 2207-2208
 hypercalcemia, 313, 2208, 2477
 hypocalcemia, 314
 hypopituitarism, 2256
 lymphadenopathy, 409
 musculoskeletal, 2209, 2209f
 neurologic, **2208**
 meningitis, 909t
 myelitis, 2656
 neuropathy, 2683
 ocular, 40e-4f, 199, 2207
 oral, 241
 pulmonary, 308e-8-9f, 308e-9f, 2206-2207, 2206f
 pulmonary hypertension, 1659
 renal, 2208
 spleen, 2208, 2208f
 weakness, 156
 complications of, 2209
 definition of, 2205
 diagnosis of
 approach to, 2209-2210, 2210f
 bronchoalveolar lavage, 1711t
 chest radiograph, 308e-8f, 308e-9f, 2206f, 2209
 CT, 308e-8f, 308e-9f, 2206f
 Kveim-Siltzbach procedures, 2210
 laboratory findings, 2209-2210
 MRI, 441e-11-15f, 2209
 PET, 2209, 2209f
 urinalysis, 62e-11f
 differential diagnosis of, 367, 2167t, 2208
 etiology of, 2205
 global considerations in, 2205
 immunopathogenesis of, 2205-2206, 2205f
 incidence of, 2205
 vs. occupational lung disease, 1691
 prognosis of, 2210
 treatment of, 1560, 2210-2212, 2211f, 2212t
- Sarcoma, **119e-1**
 bone. *See* Bone sarcoma
 cardiac, 289e-2
 deaths from, 470t
 definition of, 102e-1, 103e-1
 follicular dendritic cell, 135e-9
 gastric, 536
 genetic considerations in, 101e-3
 granulocytic, 366
 histiocytic, 135e-9
 interdigitating dendritic cell, 135e-9
 Langerhans cell, 135e-9
 metastatic, 308e-16f, 604t
 paraneoplastic syndromes in, 609t
 soft tissue. *See* Soft tissue sarcoma
 synovial, 2247
 uterine, 596, 597
- Sarcoma virus, for gene therapy delivery, 91e-1t
- Sarcomere, 265e-4
- Sarcomeric proteins, 1553, 1555t, 1556f
- Sarcopenia, 82, 94e-4
- Sarcoplasmic reticulum, 265e-6, 265e-8f, 1503
- Sarcoptes scabiei*, 2744. *See also* Scabies
- Sarcosinemia, 434e-2t
- sar* gene, 955
- Sarin. *See* Nerve agents
- SARS. *See* Severe acute respiratory syndrome (SARS)
- Saturated solution of potassium iodide (SSKI), 1354, 1354t
- Sauna taker's lung, 1681t
- Saxagliptin, 291e-7, 2414t
- Saxitoxin, 2743
- SCA. *See* Spinocerebellar ataxia (SCA)
- Scabicides, 2743-2744
- Scabies, **2744**
 clinical features of, 76e-10f, 341t, 2744
 diagnosis of, 2744
 epidemiology of, 2744
 treatment of, 246e-9, 2744-2745
- Scaffolds, for tissue engineering, 92e-1
- Scale-free network, 87e-1, 87e-2f
- Scalene maneuver, 1647
- SCAMPS, 1914
- SCAN1 (spinocerebellar ataxia with neuropathy), 451e-4t
- Scapular winging, 462e-2f, 462e-11
- Scaritoxin, 2742
- Scarlatiniform eruptions, 362-363, 362t. *See also* Rash
- Scarlet fever (second disease)
 clinical features of, 130t, 232, 362-363, 966
 differential diagnosis of, 134, 966
 epidemiology of, 130t
 etiology of, 130t, 232, 966
 rash in
 differential diagnosis of, 127
 erythematous, 25e-6f, 134
 evolution of, 130t
 scarlatiniform, 362-363, 362t, 966f
- Scavenger receptors, 291e-1f, 291e-2
- SCCmec, 961
- Scedosporium* spp., 1355, 1356
- Scedosporium* spp. infections, 1356
- SCF (stem cell factor), 372e-11t
- Schatzki's ring, 256, 1895, 1896f, 1902, 1910f
- Scheie disease, 432e-2t, 432e-6
- Schilling test, 350e-1, 350e-1t, 1938
- Schimke immunosseous dysplasia, 375e-2
- Schinz-Giedion syndrome, 135e-5
- Schirmer strip, 199
- Schistocytes, 81e-1, 726f, 729, 737
- Schistosoma* spp. *See also* Schistosomiasis
 adherence of, 145e-3
 geographic distribution of, 245e-2t, 765t, 1423t, 1425f
 laboratory identification of, 245e-1, 245e-2t, 245e-5t, 245e-6t
 life cycle of, 245e-2t, 1424, 1424f
 transmission of, 1423t, 1425
- Schistosomiasis, **1423**
 bladder cancer and, 477t, 575, 1427
 clinical features of, 152e-4t, 1426-1427
 CNS, 1427
 eosinophilia, 245e-6t
 hepatosplenic, 1426f, 1427
 intestinal, 1426-1427
 myelitis, 2657
 pulmonary, 1427, 1659
 renal, 1836t, 1849
 skin, 829, 1426
 swimmer's itch, 1426
 diagnosis of, 152e-4t, 245e-2t, 245e-3, 245e-6t, 765t, 1427
 epidemiology of, 245e-2t, 765t, 1425, 1425f
 etiology of. *See* *Schistosoma* spp.
 immunity to, 1426
 incubation period for, 152e-4t
 pathogenesis of, 1425-1426
 prevention and control of, 1428
 in returning war veterans, 152e-4t, 152e-8
- in travelers, 245e-3, 797
 treatment of, 152e-4t, 1428, 1428t
 metrifonate, 246e-10
 oxamniquine, 246e-11
 praziquantel, 246e-12, 1428t
- Schizoaffective disorder, 2721
- Schizogony, 1369
- Schizoid personality disorders, 2721
- Schizont, *Plasmodium*, 1369
- Schizophrenia, **2720**
 CATIE study of, 2722
 chemosensory alterations in, 215
 clinical features of, 2720-2721
 vs. dementia, 2608
 diabetes mellitus type 2 in, 2722
 differential diagnosis of, 2721
 epidemiology of, 2721
 genetic considerations in, 444e-1, 465e-2, 465e-4, 2721
 insomnia in, 190
 neuropathology of, 465e-3-4
 pathophysiology of, 2721
 treatment of, 2721-2722, 2722t
- Schizophreniform disorder, 2721
- Schizotypal personality disorders, 2721
- Schmid metaphyseal chondrodysplasia, 2512
- Schnitzler's syndrome, 141, 372e-8t, 2215
- Schober test, modified, 2170
- Schwann cell tumor, benign (neurofibroma), 364
- Schwannomas, 364t, 602-603. *See also* Vestibular schwannoma (acoustic neuroma)
- Schwannomatosis, familial, 599t
- Sciatica, 121, 2222, 2222f
- Sciatic neuropathy, 2692
- SCID. *See* Severe combined immunodeficiency (SCID)
- Science of medicine, 1
- Scintigraphy
 adrenal, 1619
 in fever of unknown origin, 140
 in respiratory disease, 1664
- ScI-70 (topoisomerase I), 103e-13, 372e-24t
- Sclera, blue, 1443
- Scleral icterus, 279
- Scleredema, diabetic, 2430
- Scleritis, 200
- Sclerodactyly, 375, 1649, 2159, 2159f
- Scleroderma. *See* Systemic sclerosis (scleroderma)
- Scleroderma esophagus, 1911
- Scleroderma renal crisis, 62e-9f, 1864-1865, 2158, 2162, 2164. *See also* Systemic sclerosis (scleroderma)
- Scleromyxedema (papular mucinosis), 364t, 365
- Sclerosing cholangitis. *See* Primary sclerosing cholangitis (PSC)
- "Sclerosis of the left cardioskeleton," 1471
- Sclerosteosis, 426e-5
- Sclerostin antibodies, 2503
- Sclerotherapy, for chronic venous disease, 1652
- SCN (severe congenital neutropenia), 375e-1, 2104, 2105f
- SCN1A gene mutations, 2545t, 2589
- SCN4A gene mutations, 310, 462e-18
- SCN5A gene mutations, 1472, 1496t, 1498, 1554
- SCN9A gene mutations, 1650
- Scolex, 255e-1
- Scoliosis, 118, 462e-6
- Scombroid poisoning, 267, 2743-2744
- Scopolamine
 for excess secretions, 62, 68, 69t
 for nausea and vomiting, 62, 260, 260t
 overdose/poisoning with, 473e-8t
 in terminal weaning, 67
 for vertigo, 151t
- Scorpionfish envenomation, 2740, 2742
- Scorpion sting, 2748
- Scotoma, 197, 198f, 204
- Scrapie, 453e-1t, 453e-2